Compare 10X Genomics Inc (TXG) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Yum China Holdings Inc — how do they compare? 10X Genomics Inc trades at $80.65 (market cap $10.07B), while Yum China Holdings Inc trades at $42.92 (market cap $14.11B). The key difference: Yum China Holdings Inc is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.78% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and Yum China Holdings Inc for 77 Days on average.
| TXG | YUMC | |
|---|---|---|
Market Cap | $10.07B | $14.11B |
Volume | 5,657,286 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $97.74 | $57.95 |
52-Week Low | $11.48 | $39.98 |
Typical Hold Time | 91 Days | 77 Days |
Enterprise Value | $9.59B | $15.02B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.
The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.
YUMC trades at $41.78, up 2.78% today, with a bearish technical signal despite strong fundamentals. The company shows consistent revenue growth from $9.6B in 2022 to $11.8B in 2025, with net income reaching $929M. Recent developments include the Pizza Hut brand acquisition and expansion of Burger Bar locations, while analysts maintain a 73.68% buy rating with 25.63% upside potential.
YUMC presents a value opportunity with reasonable valuation multiples (P/E 15.3, P/S 1.2) and solid profitability (ROE 17.5%). However, technical indicators show bearish momentum, and the stock faces execution risks from rapid expansion and Chinese consumer market volatility. The Q3 2026 earnings report will be critical for confirming growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
